Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

被引:182
作者
Blair, Jimmy A.
Rauh, Daniel
Kung, Charles
Yun, Cai-Hong
Fan, Qi-Wen
Rode, Haridas
Zhang, Chao
Eck, Michael J.
Weiss, William A.
Shokat, Kevan M. [1 ]
机构
[1] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA
[4] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[6] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[8] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[9] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
[10] Max Planck Gesell, Chem Genom Ctr, D-44227 Dortmund, Germany
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nchembio866
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-molecule inhibitors. We report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue. Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src). To accommodate the new covalent bond, the quinazoline core adopts positions that are different from those seen in kinase structures with reversible quinazoline inhibitors. Based on these structures, we developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe to report the fraction of kinase necessary for cellular signaling, and we used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 50 条
[1]   A chemical switch for inhibitor-sensitive alleles of any protein kinase [J].
Bishop, AC ;
Ubersax, JA ;
Petsch, DT ;
Matheos, DP ;
Gray, NS ;
Blethrow, J ;
Shimizu, E ;
Tsien, JZ ;
Schultz, PG ;
Rose, MD ;
Wood, JL ;
Morgan, DO ;
Shokat, KM .
NATURE, 2000, 407 (6802) :395-401
[2]   Crystal structures of active Src kinase domain complexes [J].
Breitenlechner, CB ;
Kairies, NA ;
Honold, K ;
Scheiblich, S ;
Koll, H ;
Greiter, E ;
Koch, S ;
Schäfer, W ;
Huber, R ;
Engh, RA .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 353 (02) :222-231
[3]   A kinase sequence database: sequence alignments and family assignment [J].
Buzko, O ;
Shokat, KM .
BIOINFORMATICS, 2002, 18 (09) :1274-1275
[4]   Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].
Carter, TA ;
Wodicka, LM ;
Shah, NP ;
Velasco, AM ;
Fabian, MA ;
Treiber, DK ;
Milanov, ZV ;
Atteridge, CE ;
Biggs, WH ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Mehta, SA ;
Patel, HK ;
Pao, W ;
Sawyers, CL ;
Varmus, H ;
Zarrinkar, PP ;
Lockhart, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016
[5]   Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].
Cohen, MS ;
Zhang, C ;
Shokat, KM ;
Taunton, J .
SCIENCE, 2005, 308 (5726) :1318-1321
[6]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[7]   The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation [J].
Cowan-Jacob, SW ;
Fendrich, G ;
Manley, PW ;
Jahnke, W ;
Fabbro, D ;
Liebetanz, J ;
Meyer, T .
STRUCTURE, 2005, 13 (06) :861-871
[8]  
DeLano W. L., 2002, PYMOL
[9]   Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer [J].
Engelman, Jeffrey A. ;
Mukohara, Toru ;
Zejnullahu, Kreshnik ;
Lifshits, Eugene ;
Borras, Ana M. ;
Gale, Christopher-Michael ;
Naumov, George N. ;
Yeap, Beow Y. ;
Jarrell, Emily ;
Sun, Jason ;
Tracy, Sean ;
Zhao, Xiaojun ;
Heymach, John V. ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2695-2706
[10]   Mechanism-based profiling of enzyme families [J].
Evans, Michael J. ;
Cravatt, Benjamin F. .
CHEMICAL REVIEWS, 2006, 106 (08) :3279-3301